Revenue GrowthSustained revenue growth of ~8% indicates continuing market demand and product traction. Over a 2–6 month horizon this provides a stable top‑line base for reinvestment in R&D and commercialization, supporting mid‑term cash generation and strategic execution.

Profitability & MarginsHigh gross and sizable EBITDA/net margins reflect durable pricing power and efficient cost structure. These margins create buffer versus downturns, enable reinvestment in pipeline and operations, and support sustainable operating leverage over the coming months.

Balance Sheet StrengthA low D/E and solid equity ratio signal financial flexibility and lower leverage risk. Combined with reported strong operating cash conversion, this balance sheet strength supports funding of development programs and cushions short‑term shocks without forcing dilutive financing.

Bears Say

Negative Free Cash FlowNegative free cash flow, despite strong operating cash conversion, suggests elevated capex or working capital demands. Over 2–6 months this can constrain discretionary investments, increase funding needs, or force prioritization of projects, reducing strategic optionality.

Earnings VolatilityA ~51% decline in EPS signals meaningful earnings volatility or one‑time pressures. Persistent earnings weakness would limit retained earnings for reinvestment, increase reliance on external funding, and raise execution risk for multi‑period development plans.

Moderate Return On EquityROE of ~14.7% is positive but not exceptional for growth biotech. Over months this indicates room to improve capital efficiency; without rising ROE, shareholder returns may lag peers and the company may need operational or portfolio changes to boost long‑term value creation.

StemCell Institute News

StemCell Institute Expands into Southeast Asia with Joint Venture

The latest announcement is out from StemCell Institute ( ($JP:7096) ). StemCell Institute Inc. has entered a joint...

8M ago

7096

7096 FAQ

What was StemCell Institute’s price range in the past 12 months?

StemCell Institute lowest stock price was ¥744.00 and its highest was ¥1462.00 in the past 12 months.

What is StemCell Institute’s market cap?

StemCell Institute’s market cap is ¥8.87B.

When is StemCell Institute’s upcoming earnings report date?

StemCell Institute’s upcoming earnings report date is May 07, 2026 which is in 60 days.

How were StemCell Institute’s earnings last quarter?

StemCell Institute released its earnings results on Feb 12, 2026. The company reported ¥6.12 earnings per share for the quarter, beating the consensus estimate of N/A by ¥6.12.

Is StemCell Institute overvalued?

According to Wall Street analysts StemCell Institute’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does StemCell Institute pay dividends?

StemCell Institute pays a Notavailable dividend of ¥25 which represents an annual dividend yield of N/A. See more information on StemCell Institute dividends here

What is StemCell Institute’s EPS estimate?

StemCell Institute’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does StemCell Institute have?

StemCell Institute has 10,246,600 shares outstanding.

What happened to StemCell Institute’s price movement after its last earnings report?

StemCell Institute reported an EPS of ¥6.12 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.296%.

Which hedge fund is a major shareholder of StemCell Institute?

Currently, no hedge funds are holding shares in JP:7096

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

StemCell Institute

StemCell Institute Inc. engages in the stem cell banking business in Japan. The company is also involved in research and development of medical treatments using stem cells, as well as engages in banking of blood vessel cells businesses. StemCell Institute Inc. was incorporated in 1999 and is headquartered in Tokyo, Japan. StemCell Institute Inc. is a subsidiary of Trim Medical Holdings Inc.